The BMT CTN Data and Coordinating Center (DCC) is pleased to announce the launch of the new and improved BMT CTN website (hubs.la/Q01fqXHr0) and the refreshed BMT CTN logo! The abstract “T” for transplant was carried into the new design, which represents the circle of life.

Exciting news! The #BMTCTN 2001 GRASP study is activated! A Multi-Center, Phase 2 Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease clinicaltrials.gov/ct2/show/NCT05… #SickleCell #CareAboutRare

Doctors should team up to diagnose acute graft-versus-host disease, or AGVHD, more accurately. That’s according to new research from the BMT CTN. Read more: cibmtr.org/ReferenceCente…

Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502) #BMTsm ⁦Amy DeZern⁩ ⁦BMT CTN⁩ ⁦AA&MDSIF⁩ #PTCy thelancet.com/journals/lanha…

Recommend Dr. Wingard's Perspectives article providing historical context of the #BMTCTN--he has a great vantagepoint as the Network's first Steering Committee Chair!

Nominations now being accepted for the new #BMTCTN Patient and Caregiver Advocacy Committee! For more information: bmtctn.net/technical-and-…

Excited to have Sumithira Vasu lead this new committee--so much important work to be done!

It's official! #BMTCTN 1703 (PROGRESS III; Acute GVHD Prophy PTCy vs. Tac/Mtx) selected as Late-Breaking Abstract at #ASH22! Congrats to the protocol team and participating sites; and special thanks the patients who participated. ash.confex.com/ash/2022/webpr…

#ASH22 LBA personally proud to see BMT CTN showing superior GRFS with PTCY in RIC #allo. Practice changing. No negative impact on OS, PFS, relapse. When surviving important to service without #gvhd OncLive.com Shernan Holtan MD Javier Bolaños Meade, MD

#Practicechanging trial presented by Shernan Holtan MD 👏👏👏 BMT CTN 1703 #bmtsm PTCY should be new SOC in RIC AlloHCT with well matched HLA donor 2/3

Iris Gersten from ⁦Emmes⁩ presented with the #BMTCTN Purple Heart award at the Steering Committee…in recognition of 20+ years working with the Network! If you see her at #Tandem23 be sure to congratulate her on her upcoming retirement! 💜

Great introduction to the #BMTCTN Coordinators Meeting by Chair Ed Stadtmauer —making sure our research coordinators know how appreciated they are! 💜 #Tandem23

Packed room for ⁦the incomparable ⁦Mary Horowitz⁩ — giving talk on trends in HCT & cellular therapies at #BMTCTN Coordinators Meeting #Tandem23

Crowd gathered at #BMTCTN booth for grip strength challenge! #Tandem23

Great #BMTCTN myeloma research & patient advocacy initiative posters await at the end of the abstract treasure hunt 😂 Poster nos. 484 & 533 #Tandem23

#BMTCTN 1704 CHARM Co-Chair ⁦Mohamed Sorror⁩ stopping by the booth to do the same grip strength test as his 1704 patients …and excitedly talking about primary results abstract that should be ready by end of this year! #Tandem23

Great reminder that the #BMTCTN 2001 GRASP study is open to accrual.

Congratulations to #BMTCTN 1703 team, investigators and their teams, and most importantly, the patients who participated. A communal effort that yielded incredible results! Javier Bolaños Meade, MD Shernan Holtan MD Mehdi Hamadani, MD

A new BMT CTN study shows that despite side effects, people who got #BMT for treating MDS had similar quality of life to people who didn’t get BMT. And people who got BMT were more likely to survive 3 years after treatment. cibmtr.org/Files/Patient-…

A new BMT CTN study shows that giving gilteritinib after BMT helps people who have FLT3 AML and have MRD. Read more about this study: cibmtr.org/Files/Patient-…